- Home
- AMBP vs PHVS Comparison
AMBP vs PHVS Comparison
Compare AMBP & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBP
- PHVS
- Stock Information
- Founded
- AMBP 2021
- PHVS 2015
- Country
- AMBP Luxembourg
- PHVS Switzerland
- Employees
- AMBP N/A
- PHVS N/A
- Industry
- AMBP Containers/Packaging
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- AMBP Industrials
- PHVS Health Care
- Exchange
- AMBP Nasdaq
- PHVS Nasdaq
- Market Cap
- AMBP 2.0B
- PHVS 1.6B
- IPO Year
- AMBP N/A
- PHVS 2021
- Fundamental
- Price
- AMBP $3.75
- PHVS $27.34
- Analyst Decision
- AMBP Hold
- PHVS Buy
- Analyst Count
- AMBP 6
- PHVS 7
- Target Price
- AMBP $4.22
- PHVS $37.00
- AVG Volume (30 Days)
- AMBP 1.2M
- PHVS 302.6K
- Earning Date
- AMBP 10-23-2025
- PHVS 11-12-2025
- Dividend Yield
- AMBP 10.67%
- PHVS N/A
- EPS Growth
- AMBP N/A
- PHVS N/A
- EPS
- AMBP N/A
- PHVS N/A
- Revenue
- AMBP $5,346,000,000.00
- PHVS N/A
- Revenue This Year
- AMBP $13.06
- PHVS N/A
- Revenue Next Year
- AMBP $2.96
- PHVS N/A
- P/E Ratio
- AMBP N/A
- PHVS N/A
- Revenue Growth
- AMBP 10.34
- PHVS N/A
- 52 Week Low
- AMBP $2.50
- PHVS $11.51
- 52 Week High
- AMBP $4.78
- PHVS $28.01
- Technical
- Relative Strength Index (RSI)
- AMBP 57.39
- PHVS 68.64
- Support Level
- AMBP $3.72
- PHVS $24.39
- Resistance Level
- AMBP $3.65
- PHVS $26.20
- Average True Range (ATR)
- AMBP 0.10
- PHVS 1.88
- MACD
- AMBP 0.03
- PHVS 0.34
- Stochastic Oscillator
- AMBP 92.00
- PHVS 94.53
About AMBP Ardagh Metal Packaging S.A.
Ardagh Metal Packaging SA is a supplier of infinitely recyclable, sustainable, metal beverage cans and ends to brand owners. The company deals with multiple categories of products including beer, carbonated soft drinks, energy drinks, hard seltzers, juices, pre-mixed cocktails, teas, sparkling waters, and wine. Its segment includes Europe and the Americas. It derives a majority of its revenue from the Americas.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.